Literature DB >> 22894961

Comparison of complement dependent lytic, hemagglutination inhibition and microneutralization antibody responses in influenza vaccinated individuals.

Mary Dawn T Co1, John Cruz, Akira Takeda, Francis A Ennis, Masanori Terajima.   

Abstract

Virus specific, non-neutralizing antibodies such as complement dependent lytic (CDL) antibodies may reduce morbidity following infection through the clearance of infectious virus particles and infected cells. We examined hemagglutination inhibition (HAI), microneutralization (MN) and CDL antibody titers to influenza A H1 and H3 virus strains in 23 healthy young adults who received the 2005-2006 trivalent inactivated influenza vaccine. Post vaccination, we detected statistically significant increases in MN and CDL antibodies but not in HAI antibodies. Statistically significantly higher fold increases in CDL antibodies post vaccination were seen compared with MN and HAI antibodies post vaccination. However, the overall fold increases were modest, likely related to the fact that most of the subjects had received influenza vaccination previously. This study showed that influenza vaccination is not only capable of increasing the level of antibodies that neutralize virus but also antibodies that can cause lysis of infected cells. The biological significance of these CDL antibodies merits further investigation in clinical studies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22894961      PMCID: PMC3579901          DOI: 10.4161/hv.21025

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  25 in total

1.  Enhancement of neutralizing activity of influenza virus-specific antibodies by serum components.

Authors:  Krystyna Mozdzanowska; Jingqi Feng; Mark Eid; Darya Zharikova; Walter Gerhard
Journal:  Virology       Date:  2006-06-14       Impact factor: 3.616

Review 2.  Humoral immunity to HIV-1: neutralization and beyond.

Authors:  M Huber; A Trkola
Journal:  J Intern Med       Date:  2007-07       Impact factor: 8.989

3.  Discordance between antibody and T cell responses in recipients of trivalent inactivated influenza vaccine.

Authors:  Mary Dawn T Co; Laura Orphin; John Cruz; Pamela Pazoles; Alan L Rothman; Francis A Ennis; Masanori Terajima
Journal:  Vaccine       Date:  2008-02-26       Impact factor: 3.641

4.  The hemagglutination inhibition antibody responses to an inactivated influenza vaccine among healthy adults: with special reference to the prevaccination antibody and its interaction with age.

Authors:  Y Hirota; M Kaji; S Ide; S Goto; T Oka
Journal:  Vaccine       Date:  1996-12       Impact factor: 3.641

5.  Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses.

Authors:  Andres G Grandea; Ole A Olsen; Thomas C Cox; Mark Renshaw; Philip W Hammond; Po-Ying Chan-Hui; Jennifer L Mitcham; Witold Cieplak; Shaun M Stewart; Michael L Grantham; Andrew Pekosz; Maki Kiso; Kyoko Shinya; Masato Hatta; Yoshihiro Kawaoka; Matthew Moyle
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-01       Impact factor: 11.205

6.  Complement-dependent lysis of influenza a virus-infected cells by broadly cross-reactive human monoclonal antibodies.

Authors:  Masanori Terajima; John Cruz; Mary Dawn T Co; Jane-Hwei Lee; Kaval Kaur; Jens Wrammert; Patrick C Wilson; Francis A Ennis
Journal:  J Virol       Date:  2011-10-12       Impact factor: 5.103

Review 7.  Influenza: old and new threats.

Authors:  Peter Palese
Journal:  Nat Med       Date:  2004-12       Impact factor: 53.440

Review 8.  Haemagglutination-inhibiting antibody to influenza virus.

Authors:  J C de Jong; A M Palache; W E P Beyer; G F Rimmelzwaan; A C M Boon; A D M E Osterhaus
Journal:  Dev Biol (Basel)       Date:  2003

9.  Rapid cloning of high-affinity human monoclonal antibodies against influenza virus.

Authors:  Jens Wrammert; Kenneth Smith; Joe Miller; William A Langley; Kenneth Kokko; Christian Larsen; Nai-Ying Zheng; Israel Mays; Lori Garman; Christina Helms; Judith James; Gillian M Air; J Donald Capra; Rafi Ahmed; Patrick C Wilson
Journal:  Nature       Date:  2008-04-30       Impact factor: 49.962

10.  A serum mannose-binding lectin mediates complement-dependent lysis of influenza virus-infected cells.

Authors:  P C Reading; C A Hartley; R A Ezekowitz; E M Anders
Journal:  Biochem Biophys Res Commun       Date:  1995-12-26       Impact factor: 3.575

View more
  9 in total

1.  Diversity of the murine antibody response targeting influenza A(H1N1pdm09) hemagglutinin.

Authors:  Jason R Wilson; Wen-Pin Tzeng; April Spesock; Nedzad Music; Zhu Guo; Robert Barrington; James Stevens; Ruben O Donis; Jacqueline M Katz; Ian A York
Journal:  Virology       Date:  2014-05-10       Impact factor: 3.616

2.  High Antibody-Dependent Cellular Cytotoxicity Antibody Titers to H5N1 and H7N9 Avian Influenza A Viruses in Healthy US Adults and Older Children.

Authors:  Masanori Terajima; Mary Dawn T Co; John Cruz; Francis A Ennis
Journal:  J Infect Dis       Date:  2015-03-20       Impact factor: 5.226

3.  Broad and Protective Influenza B Virus Neuraminidase Antibodies in Humans after Vaccination and their Clonal Persistence as Plasma Cells.

Authors:  Michael S Piepenbrink; Aitor Nogales; Madhubanti Basu; Christopher F Fucile; Jane L Liesveld; Michael C Keefer; Alexander F Rosenberg; Luis Martinez-Sobrido; James J Kobie
Journal:  mBio       Date:  2019-03-12       Impact factor: 7.867

4.  Dissecting Fc signatures of protection in neonates following maternal influenza vaccination in a placebo-controlled trial.

Authors:  Carolyn M Boudreau; John S Burke; Kiel D Shuey; Caitlin Wolf; Joanne Katz; James Tielsch; Subarna Khatry; Steven C LeClerq; Janet A Englund; Helen Y Chu; Galit Alter
Journal:  Cell Rep       Date:  2022-02-08       Impact factor: 9.995

5.  Alveolar macrophages are critical for broadly-reactive antibody-mediated protection against influenza A virus in mice.

Authors:  Wenqian He; Chi-Jene Chen; Caitlin E Mullarkey; Jennifer R Hamilton; Christine K Wong; Paul E Leon; Melissa B Uccellini; Veronika Chromikova; Carole Henry; Kevin W Hoffman; Jean K Lim; Patrick C Wilson; Matthew S Miller; Florian Krammer; Peter Palese; Gene S Tan
Journal:  Nat Commun       Date:  2017-10-10       Impact factor: 14.919

6.  Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies.

Authors:  Ram P Kamal; Kristy Blanchfield; Jessica A Belser; Nedzad Music; Wen-Pin Tzeng; Crystal Holiday; Ashley Burroughs; Xiangjie Sun; Taronna R Maines; Min Z Levine; Ian A York
Journal:  J Virol       Date:  2017-09-27       Impact factor: 5.103

7.  The Potential Role of Fc-Receptor Functions in the Development of a Universal Influenza Vaccine.

Authors:  Sinthujan Jegaskanda
Journal:  Vaccines (Basel)       Date:  2018-05-17

8.  Neutralization and hemagglutination-inhibition antibodies following influenza vaccination of HIV-infected and HIV-uninfected pregnant women.

Authors:  Marta C Nunes; Adriana Weinberg; Clare L Cutland; Stephanie Jones; David Wang; Bonnie Dighero-Kemp; Min Z Levine; Niteen Wairagkar; Shabir A Madhi
Journal:  PLoS One       Date:  2018-12-31       Impact factor: 3.240

9.  Non-neutralizing antibody responses following A(H1N1)pdm09 influenza vaccination with or without AS03 adjuvant system.

Authors:  Damien Friel; Mary Co; Thierry Ollinger; Bruno Salaun; Anne Schuind; Ping Li; Karl Walravens; Francis A Ennis; David W Vaughn
Journal:  Influenza Other Respir Viruses       Date:  2020-09-05       Impact factor: 4.380

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.